SCHEMBL2628762

SCHEMBL2628762

CC(=O)Nc1cccc(NC(=O)[C@@H]2C[C@H](C)CC[C@H]2C(C)C)c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.62
HSD17B10 Q99714 3/20 0.56
EPHX1 P07099 1/20 0.46
ALDH1A1 P00352 2/20 0.43
TRPV1 Q8NER1 2/20 0.43
TSHR P16473 2/20 0.42
POLB P06746 1/20 0.42
NR4A1 P22736 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.41
USP2 O75604 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2628752 0.89 TRPM8 (0.61) TRPM8EPHX1ALDH1A1TRPV1SMN1; SMN2
SCHEMBL4143429 0.88 TRPM8 (0.60) TRPM8HSD17B10EPHX1TRPV1NPSR1
SCHEMBL15133466 0.88 TRPM8 (0.62) TRPM8HSD17B10EPHX1ALDH1A1TRPV1
SCHEMBL10072944 0.87 TRPM8 (0.61) TRPM8HSD17B10EPHX1ALDH1A1TRPV1
SCHEMBL10073491 0.86 TRPM8 (0.73) TRPM8EPHX1POLBRAB9ASMN1; SMN2
SCHEMBL4817890 0.86 TRPM8 (0.73) TRPM8EPHX1POLBRAB9ASMN1; SMN2
SCHEMBL2628779 0.85 TRPM8 (0.58) TRPM8EPHX1ALDH1A1TRPV1
SCHEMBL299356 0.85 TRPM8 (0.58) TRPM8EPHX1ALDH1A1TRPV1
SCHEMBL10072943 0.85 TRPM8 (0.75) TRPM8ALDH1A1TRPV1POLBSMN1; SMN2
SCHEMBL2628757 0.85 TRPM8 (0.58) TRPM8HSD17B10EPHX1TRPV1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2013-07-25 US disclosed
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2013-07-25 US disclosed
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 TRPM8 10/4885HSD17B10 3885/4885EPHX1 2902/4885
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 TRPM8 8/4885HSD17B10 3871/4885EPHX1 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.